Form 4: Nautilus Biotechnology Executive Matthew Murphy Acquires Stock Options
SEC Form 4 Filing
Matthew Murphy, General Counsel of Nautilus Biotechnology, acquired 160,000 stock options on March 3, 2025, according to a recent SEC filing.
Summary
- On March 3, 2025, Matthew B. Murphy, General Counsel of Nautilus Biotechnology, Inc., acquired 160,000 stock options.
- The options have an exercise price of $1.24.
- 25% of the shares will vest on January 1, 2026, and the remainder will vest monthly over the following 36 months, contingent on continued service.
- The options expire on March 3, 2035.
- A power of attorney was executed on February 21, 2025, granting certain individuals the authority to act on Murphy's behalf in SEC filings.
Sentiment
Score: 6
Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it indicates executive alignment with company performance through stock options.
Positives
- The acquisition of stock options by a key executive could signal confidence in the company's future prospects.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel. This grant aligns with standard compensation practices in the sector.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotechnology industry, often used to align management's interests with those of shareholders.
- Comparable companies like Pacific Biosciences or Twist Bioscience also utilize stock options as part of their compensation strategy for key executives.
- The vesting schedule and exercise price are within the typical range observed for similar grants in the biotech sector.
Stakeholder Impact
- The granting of stock options can incentivize management to improve company performance, potentially benefiting shareholders.
- Employees may view the granting of options to executives as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| February 21, 2025 | Date of execution of Power of Attorney. |
| January 1, 2025 | Vesting Commencement Date. |
| March 3, 2025 | Date of transaction (acquisition of stock options). |
| March 4, 2025 | Date of filing. |
| January 1, 2026 | First vesting date (25% of shares). |
| March 3, 2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.